The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Abella, 2005, Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for hrs phosphorylation, Mol. Cell. Biol., 25, 9632, 10.1128/MCB.25.21.9632-9645.2005

Anido, 2003, ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells, Clin. Cancer Res., 9, 1274

Asaoka, 2010, Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion, Biochem. Biophys. Res. Commun., 394, 1042, 10.1016/j.bbrc.2010.03.120

Birchmeier, 2003, Met, metastasis, motility and more, Nat. Rev. Mol. Cell Biol., 4, 915, 10.1038/nrm1261

Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat. Chem. Biol., 11, 611, 10.1038/nchembio.1858

Bondeson, 2017, Lessons in PROTAC design from selective degradation with a promiscuous warhead, Cell. Chem. Biol., 25, 78, 10.1016/j.chembiol.2017.09.010

Buckley, 2012, Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α, Angew. Chem. Int. Ed., 51, 11463, 10.1002/anie.201206231

Buckley, 2015, HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins, ACS Chem. Biol., 10, 1831, 10.1021/acschembio.5b00442

Buckley, 2012, Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction, J. Am. Chem. Soc., 134, 4465, 10.1021/ja209924v

Dassonville, 2007, EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors, Crit. Rev. Oncol. Hematol., 62, 53, 10.1016/j.critrevonc.2006.12.008

Douglass, 2013, A comprehensive mathematical model for three-body binding equilibria, J. Am. Chem. Soc., 135, 6092, 10.1021/ja311795d

Drilon, 2016, MET exon 14 alterations in lung cancer: exon skipping extends half-life, Clin. Cancer Res., 22, 2832, 10.1158/1078-0432.CCR-16-0229

Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478

Field, 2017, Selective downregulation of JAK2 and JAK3 by an ATP-competitive pan-JAK inhibitor, ACS Chem. Biol., 12, 1183, 10.1021/acschembio.7b00116

Gadd, 2017, Structural basis of PROTAC cooperative recognition for selective protein degradation, Nat. Chem. Biol., 13, 514, 10.1038/nchembio.2329

Gherardi, 2012, Targeting MET in cancer: rationale and progress, Nat. Rev. Cancer, 12, 89, 10.1038/nrc3205

Graves, 2013, The dynamic nature of the kinome, Biochem. J., 450, 1, 10.1042/BJ20121456

Gschwind, 2004, The discovery of receptor tyrosine kinases: targets for cancer therapy, Nat. Rev. Cancer, 4, 361, 10.1038/nrc1360

Hines, 2013, Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs, Proc. Natl. Acad. Sci. USA, 110, 8942, 10.1073/pnas.1217206110

Hjerpe, 2009, Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities, EMBO Rep., 10, 1250, 10.1038/embor.2009.192

Iqbal, 2014, Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic Implications, Mol. Biol. Int., 2014, 852748, 10.1155/2014/852748

Jo, 2000, Cross-talk between epidermal growth factor receptor and c-met signal pathways in transformed cells, J. Biol. Chem., 275, 8806, 10.1074/jbc.275.12.8806

Joffre, 2011, A direct role for Met endocytosis in tumorigenesis, Nat. Cell Biol., 13, 827, 10.1038/ncb2257

Kermorgant, 2003, Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-met, J. Biol. Chem., 278, 28921, 10.1074/jbc.M302116200

Kim, 2005, Development and characterization of proteasome inhibitors, Methods Enzymol., 399, 585, 10.1016/S0076-6879(05)99039-3

Koga, 2007, Low dose geldanamycin inhibits hepatocyte growth factor- and hypoxia-stimulated invasion of cancer cells, Cell Cycle, 6, 1393, 10.4161/cc.6.11.4296

Konecny, 2006, Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells, Cancer Res., 66, 1630, 10.1158/0008-5472.CAN-05-1182

Kong-Beltran, 2006, Somatic mutations lead to an oncogenic deletion of Met in lung cancer, Cancer Res., 66, 283, 10.1158/0008-5472.CAN-05-2749

Kurimchak, 2016, Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer, Cell Rep., 16, 1273, 10.1016/j.celrep.2016.06.091

Lai, 2016, Modular PROTAC design for the degradation of oncogenic BCR-ABL, Angew. Chem. Int. Ed., 55, 807, 10.1002/anie.201507634

Lebraud, 2016, Protein degradation by in-cell self-assembly of proteolysis targeting chimeras, ACS Cent. Sci., 2, 927, 10.1021/acscentsci.6b00280

Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011

Lu, 2015, Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4, Chem. Biol., 22, 755, 10.1016/j.chembiol.2015.05.009

Mahalingam, 2009, Targeting HSP90 for cancer therapy, Br. J. Cancer, 100, 1523, 10.1038/sj.bjc.6605066

Miyajima, 2013, The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models, Can. Res., 73, 7022, 10.1158/0008-5472.CAN-13-1156

Neklesa, 2012, Chemical biology: greasy tags for protein removal, Nature, 487, 308, 10.1038/487308a

Neklesa, 2011, Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins, Nat. Chem. Biol., 7, 538, 10.1038/nchembio.597

Organ, 2011, An overview of the c-MET signaling pathway, Ther. Adv. Med. Oncol., 3, S7, 10.1177/1758834011422556

Pellinen, 2006, Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of β1-integrins, J. Cell Biol., 173, 767, 10.1083/jcb.200509019

Perez-Torres, 2006, Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations, J. Biol. Chem., 281, 40183, 10.1074/jbc.M607958200

Peschard, 2001, Mutation of the c-cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein, Mol. Cell, 8, 995, 10.1016/S1097-2765(01)00378-1

Pillay, 2009, The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases, Neoplasia, 11, 448, 10.1593/neo.09230

Pratz, 2009, A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response, Blood, 113, 3938, 10.1182/blood-2008-09-177030

Raina, 2016, PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer, Proc. Natl. Acad. Sci. USA, 113, 7124, 10.1073/pnas.1521738113

Sakamoto, 2001, Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation, Proc. Natl. Acad. Sci. USA, 98, 8554, 10.1073/pnas.141230798

Scagliotti, 2015, Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer, J. Clin. Oncol., 33, 2667, 10.1200/JCO.2014.60.7317

Schiedel, 2017, Chemically induced degradation of sirtuin 2 (Sirt2) by a Proteolysis targeting Chimera (PROTAC) based on sirtuin rearranging ligands (SirReals), J. Med. Chem.

Schneekloth, 2008, Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics, Bioorg. Med. Chem. Lett., 18, 5904, 10.1016/j.bmcl.2008.07.114

Sequist, 2011, Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer, J. Clin. Oncol., 29, 3307, 10.1200/JCO.2010.34.0570

Solca, 2012, Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker, J. Pharmacol. Exp. Ther., 343, 342, 10.1124/jpet.112.197756

Soucy, 2009, An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer, Nature, 458, 732, 10.1038/nature07884

Stuhlmiller, 2015, Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains, Cell Rep., 11, 390, 10.1016/j.celrep.2015.03.037

Takeuchi, 2011, Receptor tyrosine kinases and targeted cancer therapeutics, Biol. Pharm. Bull., 34, 1774, 10.1248/bpb.34.1774

Thelemann, 2005, Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells, Mol. Cell. Proteomics, 4, 356, 10.1074/mcp.M400118-MCP200

Tsao, 2001, Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer, Hum. Pathol., 32, 57, 10.1053/hupa.2001.21133

Wang, 2009, Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors, Cell Cycle, 8, 2050, 10.4161/cc.8.13.8861

Wislez, 2016, Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?, Ann. Transl. Med., 4, 96, 10.21037/atm.2016.01.12

Xie, 2014, Pharmacological targeting of the pseudokinase Her3, Nat. Chem. Biol., 10, 1006, 10.1038/nchembio.1658

Xu, 2010, Receptor tyrosine kinase coactivation networks in cancer, Can. Res., 70, 3857, 10.1158/0008-5472.CAN-10-0163

Yasuda, 2013, Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer, Sci. Transl. Med., 5, 216ra177, 10.1126/scitranslmed.3007205

Yewale, 2013, Epidermal growth factor receptor targeting in cancer: a review of trends and strategies, Biomaterials, 34, 8690, 10.1016/j.biomaterials.2013.07.100

Zengerle, 2015, Selective small molecule induced degradation of the BET bromodomain protein BRD4, ACS Chem. Biol., 10, 1770, 10.1021/acschembio.5b00216

Zhou, 2017, Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression, J. Med. Chem.

Zillhardt, 2011, Foretinib (GSK1363089), an orally available multikinase inhibitor of c-met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis, Clin. Cancer Res., 17, 4042, 10.1158/1078-0432.CCR-10-3387